CSL Share Price and Company Fundamentals
Last traded: Today at 6:10 AM
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Key Metrics
PE ratio
-
PB ratio
-
Dividend yield
0.81%
Beta
0.11
Market cap
-
Enterprise value
-
Company profile
Primary activities | Development, manufacturing and marketing of pharmaceutical and diagnostic products, cell culture media and human plasma fractions. |
---|---|
Industry / Sector | Biotechnology / Healthcare |
Full time employees | 25000 |
Website | https://www.csl.com.au |
Mailing address | 45 Poplar Road Parkville VIC 3052 Australia |
Phone / Fax | 61 3 9389 1911 / 61 3 9389 1434 |
Share registry | COMPUTERSHARE INVESTOR SERVICES PTY LIMITED |
Annual reports
Published on | Report |
---|---|
02 Sep 2021 | CSL Annual Report |
Dividends
More: CSL Dividend history, yield and payout ratio
Dividend yield
0.81%
Dividend amount
$2.22
Payout ratio
43.25%
5Y Avg. yield
1.09%
CSL paid $2.22 dividend and the ex-dividend date was 07 Mar 2022.The dividend payout ratio is 43.25%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.CSL dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
CSL's forward dividend amount is $2.85 and the forward dividend yield is 1.02%. A forward dividend yield is the percentage of a company's current stock price that it expects to pay out as dividends over a certain time period, generally 12 months. Forward dividend yields are generally used in circumstances where the yield is predictable based on past instances. If not, trailing yields, which indicate the same value over the previous 12 months, are used.
Company Executives
As of May 2022, following are the company executives and directors listed on CSL.
Name | Title | Age | Total Pay |
---|---|---|---|
Mr. Paul R. Perreault B.A. | MD, CEO & Exec. Director | 64 | 3.62M |
Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI | Chief Financial Officer | 56 | 785.02k |
Dr. Paul F. McKenzie Ph.D. | Chief Operating Officer | 55 | 2.11M |
Dr. Robert Andrew Cuthbertson A.O., AO, BMedSci, FAHMS, FTSE, MBBS, Ph.D. | Sr. Adviser & Exec. Director | 66 | 1.05M |
Mr. Mark Dehring | Head of Investor Relations | ||
Mr. Gregory Boss B.S., BS(Hons), J.D. | Exec. VP of Legal & Group Gen. Counsel | 60 | |
Christina Hickie | Sr. Mang. of Communications | ||
Ms. Elizabeth Walker B.A., M.S. | Exec. VP & Chief HR Officer | 51 | |
Dr. Karen Etchberger | Exec. VP of Quality & Bus. Services | 63 | |
Dr. Wilfried Freudenberg | Department Head of Albumin & Immunoglobulins Production |
Profitability and management effectiveness
Profit margin
21.91%
Operating margin
28.31%
Return on assets
9.13%
Return on equity
20.96%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of CSL is and its enterprise value is .
The CSL's stocks Beta value is 0.11 making it 89% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to CSL (CSL)
CSL (ASX:CSL) Frequently Asked Questions
1. What is CSL's Stock Symbol?
CSL trades on ASX under the ticker symbol "CSL".
2. What is CSL's stock price today?
One share of CSL stock can currently be purchased for approximately $273.09.
3. How can I contact CSL?
CSL's mailing address is 45 Poplar Road Parkville VIC 3052 Australia. The company can be reached via phone at 61 3 9389 1911.
4. What is CSL's official website?
The official website of CSL is https://www.csl.com.au.
5. Which share registry manages CSL's stock?
CSL's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.